Key Drivers
- Gross Margin
- Weak FCF
- Tight Coverage
AIAI Summary
AORT should now be viewed less as a pure growth medtech and more as an execution-and-cash-conversion story: NEXUS and Endospan add real strategic upside, but the recent revenue guide cut, weak free cash flow, and barely covered interest expense mean investors need proof that approvals translate into durable growth and self-funding economics before re-rating the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Weak FCF
- •Tight Coverage
AORT combines strong liquidity and gross margins with weak net profitability, thin free cash flow, and a demanding valuation, making it a cautious hold rather than an attractive buy.
Price Behavior
Key Price Behavior Insights:
- •Support Break
- •Weak Bounce
- •Damaged Trend
Over the last month, AORT has plunged from $37.72 to $22.77, broken key support, and is only tentatively stabilizing near $22, so downside risk remains elevated unless it quickly reclaims $25.41 and then the mid-$30s.
Sharp selloff from $37.72 to $22.77 after support broke on 2026-05-08
Sentiment & News
Key News Insights:
- •Revenue growth
- •FDA approval
- •Legal overhang
Artivion posted strong Q1 2026 growth and beat earnings expectations while securing FDA approval for NEXUS and advancing its aortic portfolio, but it also cut full-year revenue guidance and faces new securities-fraud legal scrutiny.
The news is mildly positive for long-term product momentum, but guidance cuts and litigation risk may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings